August 2024, Vol 15, No 1

Much progress has been made in the past 50 years since the signing of the National Cancer Act of 1971, which included the establishment of the President’s Cancer Panel. Nevertheless, there remain significant opportunities to make improvements across the cancer spectrum, perhaps none more pressing than in the realm of prevention and early detection.

An infusion of $95 million in Series C capital raise should enable a leading value cancer-care enabler to expand into new markets, invest in its existing oncology and health plan partnerships, and deepen its clinical value-based care model, according to a recently released press statement from Thyme Care.

Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups.

The variety of ongoing research in cancer has never been more dynamic. Increased understanding into the pathogenesis of cancers, intriguing research into the development of new treatments, the establishment of advanced methods of identifying actionable targets for treatment, and improved strategies for managing adverse events occurring with therapy are among the up-to-the-minute topics in the field.

The way value-based care needs to work in oncology is to pay the oncologist for managing all of the problems that occur with cancer and collaborating with other physicians to manage the noncancer illnesses.

Recently, officials with the FDA granted orphan drug designation (ODD) to alemtuzumab (CLLS52; Cellectis), which is an investigational product used as part of the lymphodepletion regimen administered before UCART22, evaluated in the BALLI-01 clinical trial in relapsed/refractory B-cell acute lymphoblastic leukemia.

Shield, Guardant Health has been FDA approved and is now covered by Medicare as the first blood test for primary colorectal cancer (CRC) screening